The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.
TSH-receptor autoimmunity in Graves' disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study
Abstract
Introduction: Autoimmunity against the TSH receptor is a key pathogenic element in Graves' disease. The autoimmune aberration may be modified by therapy of the hyperthyroidism. Objective: To compare the effects of the common types of therapy for Graves' hyperthyroidism on TSH-receptor autoimmunity. Methods: Patients with newly diagnosed Graves' hyperthyroidism aged 20–55 years were randomized to medical therapy, thyroid surgery, or radioiodine therapy (radioiodine was only given to patients ≥35 years of age). l -thyroxine ( l -T 4 ) was added to therapy as appropriate to keep patients euthyroid. Anti-thyroid drugs were withdrawn after 18 months of therapy. TSH-receptor antibodies (TRAb) in serum were measured before and for 5 years after the initiation of therapy. Results: Medical therapy ( n =48) and surgery ( n =47) were followed by a gradual decrease in TRAb in serum, with the disappearance of TRAb in 70–80% of the patients after 18 months. Radioiodine therapy ( n =36) led to a 1-year long worsening of autoimmunity against the TSH receptor, and the number of patients entering remission of TSH-receptor autoimmunity with the disappearance of TRAb from serum during the following years was considerably lower than with the other types of therapy. Conclusion: The majority of patients with Graves' disease gradually enter remission of TSH-receptor autoimmunity during medical or after surgical therapy, with no difference between the types of therapy. Remission of TSH-receptor autoimmunity after radioiodine therapy is less common.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In the group with elevated TRAb, relapse rates approach 80%-100%, while in the latter group, relapse rates are in the 20%-30% range (171,172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“TRAb assessment at the end of the course of ATD therapy is a useful method of dividing patients into two groups: one with persistent elevations who are unlikely to be in remission, and another group with low or undetectable TRAb, who have a higher probability of permanent remission (171,172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“Whereas monitoring of TRAb levels while on ATDs has been shown to be useful in adult patients for predicting the likelihood of remission or relapse of GD after stopping the medication (172), this approach has yet to be validated in children.”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
In the citing paper
“The higher risk of GO development after RAI therapy in the majority of studies may be related to the unique increase in TRAb levels observed following this therapy (172).”
From 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis (2016) · cites this paper as [172]
Citations
Cites
Relation between Therapy for Hyperthyroidism and the Course of Graves' Ophthalmopathy
Bartalena, L., Marcocci, C., Bogazzi, F., Manetti, L., Tanda, M. L., Dell'Unto, E., Bruno-Bossio, G., Nardi, M., Bartolomei, M. P., Lepri, A., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199801083380201 · Cited by 715
Occurrence of Ophthalmopathy after Treatment for Graves' Hyperthyroidism
Tallstedt, L., Lundell, G., Tørring, O., Wallin, G., Ljunggren, J.-G., Blomgren, H., & Taube, A. (1992) · New England Journal of Medicine · doi:10.1056/nejm199206253262603 · Cited by 521
Self-citationEpidemiology and Prevention of Graves' Ophthalmopathy
Wiersinga, W. M., & Bartalena, L. (2002) · Thyroid · doi:10.1089/105072502761016476 · Cited by 457
Association of thyrotrophin receptor antibodies with the clinical features of Graves' ophthalmopathy
Gerding, M. N., Meer, J. W. C. V. D., Broenink, M., Bakker, O., Wiersinga, W. M., & Prummel, M. F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00959.x · Cited by 328
Törring, O., Tallstedt, L., Wallin, G., Lundell, G. E. F., Ljunggren, J. ‐., Taube, A., Sääf, M., & Hamberger, B. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.8.8768863 · Cited by 311
Self-citationCarbimazole and the Autoimmune Response in Graves' Disease
McGregor, A. M., Petersen, M. M., McLachlan, S. M., Rooke, P., Smith, B. R., & Hall, R. (1980) · New England Journal of Medicine · doi:10.1056/nejm198008073030603 · Cited by 274
Thyrotropin receptor-associated diseases: from adenomata to Graves disease
Davies, T. F. (2005) · Journal of Clinical Investigation · doi:10.1172/jci26031 · Cited by 260
Fatourechi, V. (2005) · American Journal of Clinical Dermatology · doi:10.2165/00128071-200506050-00003 · Cited by 207
LIPPE, B. M., LANDAW, E. M., & KAPLAN, S. A. (1987) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-64-6-1241 · Cited by 192
Laurberg, P., Nygaard, B., Glinoer, D., Grussendorf, M., & Orgiazzi, J. (1998) · European Journal of Endocrinology · doi:10.1530/eje.0.1390584 · Cited by 191
Self-citation
Research works printed but not linked: 8
- 1992, New England Journal of Medicine, 25, 1733
- Torring, 1996, Journal of Clinical Endocrinology & Metabolism, 81, 2986, 10.1210/jc.81.8.2986 · DOI
- Smith, 2004, Thyroid : official journal of the American Thyroid Association, 14, 830, 10.1089/1050725042451248 · DOI
- 1980, New England Journal of Medicine, 7, 302
- Kung, 1994, Journal of Clinical Endocrinology & Metabolism, 79, 542, 10.1210/jc.79.2.542 · DOI
- 1998, New England Journal of Medicine, 8, 73
- 1979, JAMA, 30, 2408
- 2005, New England Journal of Medicine, 3, 905
Cited by
Sorted by citations
Items 201–300 of 430
Amashukeli, M., Korinteli, M., Zerekidze, T., Jikurauli, N., Shanava, S., Tsagareli, M., & Giorgadze, E. (2013) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e31828fcafb · Cited by 11
Shahida, B., Tsoumani, K., Planck, T., Modhukur, V., Asp, P., Sundlöv, A., Tennvall, J., Åsman, P., Lindgren, O., & Lantz, M. (2021) · Endocrine · doi:10.1007/s12020-021-02952-2 · Cited by 11
Ohrling, H., Törring, O., Yin, L., Iliadou, A. N., Tullgren, O., Abraham‐Nordling, M., Wallin, G., Hall, P. N., & Lönn, S. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-1168 · Cited by 11
Self-citationSawicka‐Gutaj, N., & Sowiński, J. (2012) · PubMed · Cited by 11
Diagnosis and Management of Graves’ Disease in Thailand: A Survey of Current Practice
Sriphrapradang, C. (2020) · Journal of Thyroid Research · doi:10.1155/2020/8175712 · Cited by 11
Diagnosis and Management of Fetal and Neonatal Thyrotoxicosis
Bohîlțea, R. E., Mihai, B.-M., Szini, E., Șucaliuc, I.-A., & Badiu, C. (2022) · Medicina · doi:10.3390/medicina59010036 · Cited by 11
Côté‐Bigras, S., Tran, V., Turcotte, S., Rola‐Pleszczynski, M., Verreault, J., & Rottembourg, D. (2015) · Endocrine · doi:10.1007/s12020-015-0832-2 · Cited by 14
Graves' orbitopathy: a multidisciplinary approach
Limone, P. P., Mellano, M., Redda, M. G. R., Macera, A., Ferrero, V., Franceschini, S. S., & Deandrea, M. (2021) · The Quarterly Journal of Nuclear Medicine and Molecular Imaging · doi:10.23736/s1824-4785.21.03350-1 · Cited by 11
Preoperative Subclinical Hyperthyroidism in Patients With Papillary Thyroid Carcinoma
Ahn, D., Sohn, J. H., Jeon, J., & Park, J. (2014) · Clinical and Experimental Otorhinolaryngology · doi:10.3342/ceo.2014.7.4.312 · Cited by 10
Thyroid and Parathyroid Diseases in Pregnancy
Mestman, J. H. (2007) · Elsevier eBooks · doi:10.1016/b978-0-443-06930-7.50040-2 · Cited by 10
de Morais, N. S., Angell, T. E., Ahmadi, S., Alexander, E. K., Teixeira, P. D. F. D. S., & Marqusee, E. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.01.007 · Cited by 10
Yu, H., & Farahani, P. (2015) · Clinical and investigative medicine · doi:10.25011/cim.v38i1.22574 · Cited by 10
Kelly, T. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.01.016 · Cited by 10
How to manage Graves’ disease in women of childbearing potential
Ashkar, C., Sztal‐Mazer, S., & Topliss, D. J. (2022) · Clinical Endocrinology · doi:10.1111/cen.14705 · Cited by 9
Sphingolipids in thyroid eye disease
Gulbins, A., Görtz, G.-E., Gulbins, E., & Eckstein, A. K. (2023) · Frontiers in Endocrinology · doi:10.3389/fendo.2023.1170884 · Cited by 9
Grulet, H., Barraud, S., Chikh, K., Souchon, P. F., Claris, O., Bouvier, R., Trouillas, J., Gabriel, R., Bory, J. P., Schvartz, C., et al. (2019) · Thyroid · doi:10.1089/thy.2018.0098 · Cited by 9
Comparison of two different TSH-receptor antibody assays: A clinical practice study
van Balkum, M., Schreurs, M. W. J., Visser, W. E., Peeters, R. P., & Dik, W. A. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22468 · Cited by 9
Król, A., Koehler, A., Nowak, M., Paliczka-Cieślik, E., Krajewska, J., Kalemba, M., Jurecka‐Lubieniecka, B., Hasse-Lazar, K., Michalik, B., Szpak‐Ulczok, S., et al. (2014) · Endokrynologia Polska · doi:10.5603/ep.2014.0006 · Cited by 9
Lhotta, K., Zitt, E., Sprenger-Mähr, H., Loacker, L., & Becherer, A. (2018) · Case Reports in Endocrinology · doi:10.1155/2018/5747969 · Cited by 9
Villagelin, D., dos Santos, R. B., & Romaldini, J. H. (2020) · Intern J Endocrinol Metab · doi:10.5812/ijem.101473 · Cited by 9
Suzuki, N., Yoshihara, A., Noh, J. Y., Kinoshita, K., Ohnishi, J., Saito, M., Sugino, K., & Ito, K. (2020) · Endocrine Journal · doi:10.1507/endocrj.ej20-0039 · Cited by 8
Huang, Y., Jin, B., Huang, Y., & Dong, A. (2022) · Laboratory Medicine · doi:10.1093/labmed/lmac008 · Cited by 8
Time to Symptom Resolution After Total Thyroidectomy for Graves’ Disease
Gillis, A., Obiarinze, R. N., McLeod, M. C., Zmijewski, P. V., Chen, H., Fazendin, J. M., & Lindeman, B. M. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.07.027 · Cited by 8
TSH receptor autoantibody levels post-total thyroidectomy in Graves’ ophthalmopathy: a meta-analysis
Anees, A., Ayeni, F. E., Eslick, G. D., & Edirimanne, S. (2023) · Langenbeck s Archives of Surgery · doi:10.1007/s00423-023-03153-3 · Cited by 8
The prognostic value of thyroid-stimulating immunoglobulin in the management of Graves’ disease
Zhou, Y., Zhou, M., Qi, Y., Wang, W., Chen, X., & Wang, S. (2021) · Therapeutic Advances in Endocrinology and Metabolism · doi:10.1177/20420188211044943 · Cited by 8
Lertwattanarak, R., Kunavisarut, T., & Sriussadaporn, S. (2022) · International Journal of Endocrinology · doi:10.1155/2022/1705740 · Cited by 8
Severe fetal and neonatal hyperthyroidism years after surgical treatment of maternal Graves’ disease
Dierickx, I., Decallonne, B., Billen, J., Vanhole, C., Lewi, L., Catte, L. D., & Verhaeghe, J. (2014) · Journal of Obstetrics and Gynaecology · doi:10.3109/01443615.2013.831044 · Cited by 8
Elevated levels of circulating thyroid hormone do not cause the medical sequelae of hyperthyroidism
Kelly, T., Denmark, L., & Lieberman, D. Z. (2016) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2016.06.001 · Cited by 8
Fadeev, V. V. (2020) · Clinical and experimental thyroidology · doi:10.14341/ket12474 · Cited by 9
A Review of Autoimmune Thyroid Diseases and Their Complex Interplay with Female Fertility
Carafone, L. E., Knutson, A. J., & Gigliotti, B. J. (2024) · Seminars in Reproductive Medicine · doi:10.1055/s-0044-1795160 · Cited by 10
Kalra, S., Selim, S., Shrestha, D., Somasundaram, N. P., Raza, S. A., Baruah, M., Bhattacharya, S., GADVE, S. S., Bantwal, G., & Sahay, R. K. (2024) · BMC Endocrine Disorders · doi:10.1186/s12902-024-01809-9 · Cited by 7
Occurrence of Graves’ Orbitopathy and Graves’ Hyperthyroidism after a Trauma to the Eye
Sabini, E., Ionni, I., Rocchi, R., Vitti, P., Marcocci, C., & Marinò, M. (2017) · European Thyroid Journal · doi:10.1159/000479629 · Cited by 7
Alemtuzumab-induced thyroid eye disease successfully treated with a single low-dose of rituximab
Muller, I., Maioli, S., Armenti, M., PORCARO, L. L., Currò, N., Iofrida, E. F., Pignataro, L., Manso, J., Mian, C., Geginat, J., et al. (2024) · European Thyroid Journal · doi:10.1530/etj-23-0236 · Cited by 7
Bjørgaas, M. R., Farstad, H., Christiansen, S. C., & Blaas, H.-G. K. (2012) · Hormone Research in Paediatrics · doi:10.1159/000342644 · Cited by 7
Cui, Y., & Rijhsinghani, A. (2019) · American Journal of Perinatology Reports · doi:10.1055/s-0039-1694035 · Cited by 7
Czarnywojtek, A., Zgorzalewicz-Stachowiak, M., Budny, B., Waśko, R., Florek, E., Szczepanek, E., Komar-Rychlicka, K., Waligórska‐Stachura, J., Kurdybacha, P., Miechowicz, I., et al. (2013) · PubMed · Cited by 7
Wole guzowate olbrzymie — ambulatoryjne leczenie radiojodem
Kaniuka‐Jakubowska, S., Lewczuk, A., Mizan‐Gross, K., Piskunowicz, M., Zapaśnik, A., Lass, P., & Sworczak, K. (2015) · Endokrynologia Polska · doi:10.5603/ep.2015.0038 · Cited by 7
McLachlan, S. M., Aliesky, H. A., & Rapoport, B. (2019) · The Journal of Immunology · doi:10.4049/jimmunol.1900038 · Cited by 7
Hammerstad, S. S., Celius, E. G., Husby, H., Sørensen, I. M., & Norheim, I. (2021) · Journal of the Endocrine Society · doi:10.1210/jendso/bvab044 · Cited by 7
Nagata, K., Hayashi, K., Kumata, K., Satoh, Y., Osaki, M., Nakayama, Y., Kuwamoto, S., Ichihara, Y., Okura, T., Matsuzawa, K., et al. (2023) · Endocrine Journal · doi:10.1507/endocrj.ej22-0609 · Cited by 6
Effect of intravenous methylprednisolone on serum antibody levels in thyroid eye disease
Lee, C., Lee, J. E., Kim, K., & Woo, K. I. (2024) · British Journal of Ophthalmology · doi:10.1136/bjo-2024-325180 · Cited by 6
Tratamiento del hipertiroidismo por Enfermedad de Graves en pacientes adultos no embarazadas
Ana Fadel, A., Gutiérrez, S., Novelli, J. L., Orlandi, A. M., Parma, R., Croome, M. D. C. S., Chebel, G., Guardia, M., Guido, P., Gilligan, M., et al. (2013) · Revista Argentina de Endocrinología y Metabolismo · Cited by 6
Factitious thyrotoxicosis: how to find it
Vorasart, P., & Sriphrapradang, C. (2019) · Diagnosis · doi:10.1515/dx-2019-0015 · Cited by 6
Schott, M. (2013) · Der Internist · doi:10.1007/s00108-012-3196-1 · Cited by 6
Pregnancy after definitive treatment for G raves’ disease – Does treatment choice influence outcome?
Elston, M. S., Tu'akoi, K., Meyer-Rochow, G. Y., Tamatea, J. A. U., & Conaglen, J. V. (2014) · Australian and New Zealand Journal of Obstetrics and Gynaecology · doi:10.1111/ajo.12196 · Cited by 6
Leo, M., Sabini, E., Ionni, I., Sframeli, A. T., Mazzi, B., Menconi, F., Molinaro, E., Bianchi, F., Brozzi, F., Santini, P., et al. (2017) · Journal of Endocrinological Investigation · doi:10.1007/s40618-017-0754-3 · Cited by 6
How do paediatricians use and monitor antithyroid drugs in the UK? A clinician survey
Lawrence, N., Cheetham, T. D., & Elder, C. J. (2019) · Clinical Endocrinology · doi:10.1111/cen.14046 · Cited by 6
Shifting Trends and Informed Decision-Making in the Management of Graves' Disease
Seib, C. D., Chen, J., & Iagaru, A. H. (2020) · Thyroid · doi:10.1089/thy.2020.0114 · Cited by 6
Marinò, M., Vitti, P., & Chiovato, L. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00082-2 · Cited by 7
Radioiodine Treatment in Patients with Graves’ Disease
Ross, D. S. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_7 · Cited by 6
Chang, L., Chang, C.-C., Chen, P., Wang, S.-H., Chen, Y., Tsai, Y.-H., Shih, S., Chiu, W., Fann, C. S. J., Yang, W., et al. (2018) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2018.1502747 · Cited by 6
Ogilvy‐Stuart, A. (2017) · NeoReviews · doi:10.1542/neo.18-7-e422 · Cited by 6
Jankovski, L., Grosek, Š., Tanšek, M. Ž., Šimic, M. V., & Zaletel, K. (2024) · Children · doi:10.3390/children11080968 · Cited by 5
Giordani, I., & Sykiotis, G. P. (2024) · HORMONES · doi:10.1007/s42000-024-00618-y · Cited by 7
van Hulsteijn, L. T., Prins, J. R., Scheffer‐Rath, M. E. A., van Trotsenburg, A. S. P., Links, T. P., & Dullaart, R. P. F. (2023) · Hormone Research in Paediatrics · doi:10.1159/000530725 · Cited by 5
Current Therapeutic Approaches for Gravesʼ Orbitopathy – are Targeted Therapies the Future?
Eckstein, A. K., Stöhr, M., Görtz, G.-E., Gulbins, A., Möller, L. C., Fuehrer-Sakel, D., & Oeverhaus, M. (2023) · Klinische Monatsblätter für Augenheilkunde · doi:10.1055/a-2186-5548 · Cited by 5
Autoimmune switch from hyperthyroidism to hypothyroidism in Graves’ disease
Padmanaban, P., & Jain, R. (2020) · BMJ Case Reports · doi:10.1136/bcr-2020-236465 · Cited by 5
Clinical Application of Thyrotropin Receptor Antibodies
Yang, Y., & Chen, H. (2024) · Hormone and Metabolic Research · doi:10.1055/a-2498-8050 · Cited by 4
Risk factors and outcomes of Graves’ orbitopathy after radioactive iodine therapy
Ahn, H. Y., Lee, J., Kim, M., & Lee, J. K. (2025) · Endocrine · doi:10.1007/s12020-025-04350-4 · Cited by 4
Park, J., Kim, J. H., Choi, H. Y., Kim, J., Kim, S. S., & Yang, S.-W. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051734 · Cited by 4
British Thyroid Association Survey of Graves' Disease Management in the UK
Atkinson, M., Agrawal, M., Muralidhara, K., Abraham, P., Vaidya, B., & Okosieme, O. E. (2025) · Clinical Endocrinology · doi:10.1111/cen.15266 · Cited by 4
A Weighted Genetic Risk Score Using Known Susceptibility Variants to Predict Graves Disease Risk
Ma, Y., Zhao, S., Li, L., Sun, F., Ye, X., Yuan, F., Jiang, D., Zhou, Z., Zhang, Q.-Y., Wan, Y., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01551 · Cited by 4
Thewjitcharoen, Y., Chatchomchuan, W., Hussamon, P., Panita, S., Butadej, S., Nakasatien, S., Wanothayaroj, E., Rajatanavin, R., & Himathongkam, T. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e09471 · Cited by 4
Abalovich, M., Alcaraz, G., Ase, E., Bergoglio, L., Cabezón, C., Gutierrez, S., Iorcansky, S., de Mereshian, P. S., Pappalardo, V., Quiroga, S., et al. (2016) · Revista Argentina de Endocrinología y Metabolismo · doi:10.1016/j.raem.2016.05.003 · Cited by 5
Preconception Counseling and Care for Pregnant Women with Thyroid Disease
Dhillon‐Smith, R. K., & Boelaert, K. (2022) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2021.12.005 · Cited by 4
Immunopathogenesis of Graves’ Disease
Rapoport, B., & McLachlan, S. M. (2015) · Springer eBooks · doi:10.1007/978-1-4939-2534-6_2 · Cited by 4
Endokrine Orbitopathie aus internistischer Sicht
Laubner, K., Weber, W., & Seufert, J. (2011) · Der Ophthalmologe · doi:10.1007/s00347-010-2185-9 · Cited by 4
Smith, B. R., Sanders, J. F., & Furmaniak, J. (2008) · Biomarkers in Medicine · doi:10.2217/17520363.2.6.567 · Cited by 4
Wiersinga, W. M. (2010) · Humana Press eBooks · doi:10.1007/978-1-60327-478-4_29 · Cited by 4
Kim, K. J., Song, E., Kim, M., Kwon, H., Ku, E. J., Kwon, H. W., Yoon, J. H., Lee, E. K., Lee, W. W., Park, Y. J., et al. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2464 · Cited by 3
Zheng, X., Zhu, Y., Chen, M. G., Su, Y. C., & Wu, X. M. (2025) · BMC Surgery · doi:10.1186/s12893-025-03081-7 · Cited by 3
Chen, Z., Xu, J., Kang, W., Zhang, Y., Chen, R., & Gong, X. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2025.2405 · Cited by 3
Xu, C., Wei, L., & Xie, P. (2025) · Thyroid Research · doi:10.1186/s13044-025-00242-x · Cited by 3
Buldygina, Y. V., Strafun, L. S., Terekhova, H. М., Shlyakhtych, S. L., & Pankiv, V. І. (2019) · INTERNATIONAL JOURNAL OF ENDOCRINOLOGY (Ukraine) · doi:10.22141/2224-0721.15.2.2019.166111 · Cited by 3
Kwee, A. K., Yong, K.-L., Seah, L. L., & Chng, C. L. (2021) · Journal of the ASEAN Federation of Endocrine Societies · doi:10.15605/jafes.036.02.08 · Cited by 3
Purnamasari, D., Wildan, A., Kurniawan, J., Mulansari, N. A., Karim, B., & Yulian, E. D. (2023) · Intern J Endocrinol Metab · doi:10.5812/ijem-136608 · Cited by 3
Fetal Hyperthyroidism Secondary to Maternal Basedow–Graves' Disease
Julio Soto, B., Weissglas, B., von Plessing-Pierry, G., del Solar, M. P., Peña-Villa, C., Flores, X., Arancibia, M., & Campos, L. (2024) · American Journal of Perinatology Reports · doi:10.1055/a-2317-9431 · Cited by 3
Percutaneous triamcinolone injection for upper eyelid retraction in thyroid eye disease
Parsons, S. R., Wilson-Pogmore, A. A., & Sullivan, T. J. (2024) · Frontiers in Ophthalmology · doi:10.3389/fopht.2024.1388197 · Cited by 3
Okamura, K. (2024) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2079 · Cited by 3
Burch, H. B., & Bahn, R. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-323-18907-1.00083-4 · Cited by 3
A prospective study among neonates born to mothers with active or past Graves disease
Cano, I. D. C., Cano, R. A., Encinas, B., Ornaechea, N. L., Royuela, A., & Gabriel, M. Á. M. (2022) · Gynecological Endocrinology · doi:10.1080/09513590.2022.2073347 · Cited by 3
Graves' ophthalmopathy in patients treated with radioiodine 131-I.
Bałdys‐Waligórska, A., Gołkowski, F., Kuśnierz‐Cabala, B., Buziak‐Bereza, M., & Hubalewska–Dydejczyk, A. (2011) · PubMed · Cited by 3
Jagiełło-Korzeniowska, A., Sokołowski, A., Krzentowska, A., Miklaszewska, G., & Bałdys‐Waligórska, A. (2016) · Endokrynologia Polska · doi:10.5603/ep.2016.0073 · Cited by 3
Graves disease and metastatic hormonal-active Hürthle cell thyroid cancer
Bešič, N., Vidergar‐Kralj, B., Zaletel, K., & Kuhar, C. G. (2021) · Medicine · doi:10.1097/md.0000000000026384 · Cited by 3
Aktolun, C., & Urhan, M. (2012) · Springer eBooks · doi:10.1007/978-1-4614-4021-5_17 · Cited by 3
Peters, C. J., & Schoenmakers, N. A. (2019) · Wiley eBooks · doi:10.1002/9781119152712.ch8 · Cited by 3
Treatment of patients with hyperthyroidism and liver failure: a retrospective cohort study
Li, Z., Li, X., Shao, X., Xu, Q., Wu, Y., & Liu, Y. (2025) · BMC Gastroenterology · doi:10.1186/s12876-025-04286-z · Cited by 2
Graves’ Disease: What Is the Role and Timing of Surgery?
Elfenbein, D. M., & Sippel, R. S. (2015) · Springer eBooks · doi:10.1007/978-3-319-20523-6_8 · Cited by 2
Listewnik, M. H., Piwowarska-Bilska, H., Jasiakiewicz, K., & Birkenfeld, B. (2021) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/137779 · Cited by 2
LAFRANCHI, S. H. (2011) · Elsevier eBooks · doi:10.1016/b978-1-4377-0755-7.00562-5 · Cited by 2
de Souza, M. V. R., Sapienza, M. T., Brito, L. P., Cortêz, P. A., & Marui, S. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf016 · Cited by 2
Yu, Y., Liu, Q., Liu, D., Wang, D., Yang, L., & Ye, S. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10688 · Cited by 2
Weetman, A. P. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-812102-3.00040-3 · Cited by 2
Preconceptional Counseling in Women with Hyperthyroidism
Cima, L., Tarna, M., Martin, C. S., Sîrbu, A. M., Soare, I. S., Panaitescu, A. M., Gică, N., Barbu, C. G., & Fica, S. V. (2024) · Medicina · doi:10.3390/medicina60020234 · Cited by 2
Hosoda, A., Arata, N., Umehara, N., SATO, S. T., Sankoda, A., Iimura, Y., Mito, A., Nagata, C., Wada, S., Kawaguchi, H., et al. (2025) · Endocrine Journal · doi:10.1507/endocrj.ej24-0434 · Cited by 2
Botina, H. D. G., Ramírez, N. C., & Barrera, C. A. B. (2013) · IATREIA · doi:10.17533/udea.iatreia.14372 · Cited by 2
Thyroid Autoimmunity and Miscarriage
Acharya, K. S., & Eaton, J. L. (2018) · Springer eBooks · doi:10.1007/978-3-319-99079-8_10 · Cited by 2
Campbell, A. A., & Kazim, M. (2019) · Springer eBooks · doi:10.1007/978-3-030-10886-1_29 · Cited by 2
Walasik‐Szemplińska, D., Kamiński, G., & Sudoł‐Szopińska, I. (2020) · Journal of Ultrasound in Medicine · doi:10.1002/jum.15401 · Cited by 2
Evaluating the Thyroid Eye Disease Patient
Denisova, K., & Barmettler, A. (2021) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000351 · Cited by 3
Metadata
- Authors
- Laurberg, P., Wallin, G., Tallstedt, L., Abraham-Nordling, M., Lundell, G., & Tørring, O.
- Affiliations
- Aalborg University Hospital (DK)
- Karolinska University Hospital (SE)
- Karolinska Institutet (SE)
- Corresponding author
- Laurberg, Peter
- ORCID
- Wallin, Göran
- Venue
- European Journal of Endocrinology
- Publisher
- Oxford University Press (OUP)
- Published
- 2008-01
- Volume
- 158
- Issue
- 1
- Pages
- 69-75
- ISSN
- 0804-4643 (ISSN-L)
- 1479-683X
- OpenAlex
- W2161176285
- Cited by
- 428
- References
- 36
- Citations by year
- 2026: 7 · 2025: 32 · 2024: 22 · 2023: 19 · 2022: 30 · 2021: 31 · 2020: 30 · 2019: 28 · 2018: 30 · 2017: 19 · 2016: 19 · 2015: 29 · 2014: 28 · 2013: 21 · 2012: 27
- FWCI
- 8.04
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Journal of Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Thyroid Disorders and Treatments
- Health Sciences › Medicine › Ophthalmology › Ophthalmology and Eye Disorders
- Health Sciences › Medicine › Surgery › Thyroid and Parathyroid Surgery
- Keywords
- Graves' disease, TSH receptor antibodies, antithyroid drugs, thyroid surgery, radioiodine therapy, hyperthyroidism treatment, levothyroxine
- MeSH terms
- Adult, Autoantibodies, Graves Disease, Humans, Iodine Radioisotopes, Middle Aged, Prospective Studies, Receptors, Thyrotropin, Antithyroid Agents, Thyroidectomy, Thyroxine, Time Factors, Triiodothyronine, Autoimmunity, Treatment Outcome, Immunoglobulins, Thyroid-Stimulating
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
